These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 17126996)

  • 1. Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease.
    Oberthuer A; Warnat P; Kahlert Y; Westermann F; Spitz R; Brors B; Hero B; Eils R; Schwab M; Berthold F; Fischer M
    Cancer Lett; 2007 Jun; 250(2):250-67. PubMed ID: 17126996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
    Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
    BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of gene expression-based classification for neuroblastoma.
    Oberthuer A; Hero B; Berthold F; Juraeva D; Faldum A; Kahlert Y; Asgharzadeh S; Seeger R; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Vermeulen J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Weber A; Christiansen H; Grundy RG; Schardt K; Schwab M; Eils R; Warnat P; Kaderali L; Simon T; Decarolis B; Theissen J; Westermann F; Brors B; Fischer M
    J Clin Oncol; 2010 Jul; 28(21):3506-15. PubMed ID: 20567016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
    Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
    J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
    Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
    Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
    De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J
    Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
    Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
    Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome.
    Schramm A; Vandesompele J; Schulte JH; Dreesmann S; Kaderali L; Brors B; Eils R; Speleman F; Eggert A
    Clin Cancer Res; 2007 Mar; 13(5):1459-65. PubMed ID: 17332289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression of cell cycle genes distinguishes aggressive neuroblastoma.
    Krasnoselsky AL; Whiteford CC; Wei JS; Bilke S; Westermann F; Chen QR; Khan J
    Oncogene; 2005 Feb; 24(9):1533-41. PubMed ID: 15592497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory.
    Albino D; Scaruffi P; Moretti S; Coco S; Truini M; Di Cristofano C; Cavazzana A; Stigliani S; Bonassi S; Tonini GP
    Cancer; 2008 Sep; 113(6):1412-22. PubMed ID: 18671248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction.
    Schramm A; Mierswa I; Kaderali L; Morik K; Eggert A; Schulte JH
    Cancer Lett; 2009 Sep; 282(1):55-62. PubMed ID: 19349112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma.
    Koppen A; Ait-Aissa R; Koster J; van Sluis PG; Ora I; Caron HN; Volckmann R; Versteeg R; Valentijn LJ
    Eur J Cancer; 2007 Nov; 43(16):2413-22. PubMed ID: 17826980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization and classification of neuroblastoma.
    Oberthuer A; Theissen J; Westermann F; Hero B; Fischer M
    Future Oncol; 2009 Jun; 5(5):625-39. PubMed ID: 19519203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall genomic pattern is a predictor of outcome in neuroblastoma.
    Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
    J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma.
    Nowacki S; Skowron M; Oberthuer A; Fagin A; Voth H; Brors B; Westermann F; Eggert A; Hero B; Berthold F; Fischer M
    Oncogene; 2008 May; 27(23):3329-38. PubMed ID: 18084322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo identification of MIZ-1 (ZBTB17) encoding a MYC-interacting zinc-finger protein as a new favorable neuroblastoma gene.
    Ikegaki N; Gotoh T; Kung B; Riceberg JS; Kim DY; Zhao H; Rappaport EF; Hicks SL; Seeger RC; Tang XX
    Clin Cancer Res; 2007 Oct; 13(20):6001-9. PubMed ID: 17947461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds.
    De Preter K; De Brouwer S; Van Maerken T; Pattyn F; Schramm A; Eggert A; Vandesompele J; Speleman F
    Clin Cancer Res; 2009 Jun; 15(11):3690-6. PubMed ID: 19435837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis.
    van Gils W; Lodder EM; Mensink HW; Kiliç E; Naus NC; Brüggenwirth HT; van Ijcken W; Paridaens D; Luyten GP; de Klein A
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4254-62. PubMed ID: 18552379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results.
    Galamb O; Sipos F; Solymosi N; Spisák S; Krenács T; Tóth K; Tulassay Z; Molnár B
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2835-45. PubMed ID: 18843029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma.
    Kuroda T; Morikawa N; Matsuoka K; Fujino A; Honna T; Nakagawa A; Kumagai M; Masaki H; Saeki M
    J Pediatr Surg; 2008 Dec; 43(12):2182-5. PubMed ID: 19040931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.